Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT01590615
First received: March 20, 2012
Last updated: April 20, 2017
Last verified: April 2017
  Purpose
This registry will remain open for approximately 5 years (4 years of enrollment + 1 year of follow up). Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry.

Condition Intervention
Hepatitis B
Drug: Anti-HBV nucleoside/nucleotide therapy

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 1 Year
Official Title: Observational, Post-marketing Renal Safety Surveillance Registry in Subjects With Chronic Hepatitis B (HBV) Infection With Decompensated Liver Disease Receiving Nucleotide/Side Therapy

Resource links provided by NLM:


Further study details as provided by Gilead Sciences:

Primary Outcome Measures:
  • Proportion of participants with a confirmed increase in serum creatinine from baseline of at least one grade [ Time Frame: Baseline to Year 5 ]
    The proportion of participants with a confirmed increase in serum creatinine of at least one grade will be calculated as the number of participants with at least one grade increase in serum creatinine from baseline divided by the total number of subjects enrolled over the 4 years of accrual.


Secondary Outcome Measures:
  • Proportion of participants with a confirmed increase in serum creatinine from baseline of at least one grade evaluated using the competing risk cumulative incidence framework [ Time Frame: Baseline to Year 5 ]
  • Proportion of participants with at least one confirmed estimated glomerular filtration rate (eGFR) below 50 mL/min [ Time Frame: Baseline to Year 5 ]
  • Change in eGFR compared to eGFR at baseline by visit window [ Time Frame: Baseline to Year 5 ]
  • Proportion of participants who received appropriate dosing relative to renal function [ Time Frame: Baseline to Year 5 ]
  • Proportion of participants who discontinued anti-hepatitis B virus (HBV) nucleoside/nucleotide therapy due to a renal related event [ Time Frame: Baseline to Year 5 ]
  • Proportion of participants with at least one change in model for end stage liver disease (MELD) score compared to baseline [ Time Frame: Baseline to Year 5 ]
  • Change in MELD score and liver disease status compared to MELD score at baseline by visit window [ Time Frame: Baseline to Year 5 ]
  • Proportion of participants with at least one plasma HBV DNA < 400 copies/mL (69 IU/mL) [ Time Frame: Baseline to Year 5 ]
  • The median number of renal related adverse events per participant over the evaluation period [ Time Frame: Baseline to Year 5 ]
    Renal related adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) Preferred Term.


Enrollment: 54
Actual Study Start Date: April 26, 2012
Study Completion Date: April 4, 2017
Primary Completion Date: April 4, 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Participants with chronic HBV infection
Participants with decompensated liver disease due to chronic HBV infection, who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy, will be included in the study.
Drug: Anti-HBV nucleoside/nucleotide therapy
Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult participants with chronic HBV infection receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy and with decompensated liver disease at time of consent.
Criteria

Key Inclusion Criteria:

  • Estimated glomerular filtration rate (Cockcroft-Gault method)using actual body weight of ≥ 50 mL/min at time of entry into registry
  • Negative serologies for HIV, hepatitis C virus (HCV), and/or hepatitis D virus (HDV)
  • No history of solid organ or bone marrow transplant
  • Currently receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy within 6 months of inclusion into registry

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01590615

  Show 27 Study Locations
Sponsors and Collaborators
Gilead Sciences
Investigators
Study Director: Gilead Study Director Gilead Sciences
  More Information

Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT01590615     History of Changes
Other Study ID Numbers: GX-US-174-0172
Study First Received: March 20, 2012
Last Updated: April 20, 2017

Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Gilead Sciences:
Hepatitis
Hepatitis B
HBV
OLT
MELD
Renal Safety
Liver Transplant

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis B
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections

ClinicalTrials.gov processed this record on May 23, 2017